The denosumab biosimilar market is poised for disruption with 3 FDA-approved biosimilars, at least 5 awaiting approval, and ...
The US Food and Drug Administration has approved Celltrion's biosimilar of Johnson & Johnson's Remicade (infliximab) - but the launch date of the blockbuster's cheaper rival remains uncertain.
This is likely to limit J&J’s ability to seek damages from Pfizer, which has launched a biosimilar of Remicade ‘at risk’ in late 2016. Latest figures show that Remicade’s sales are ...
It has been 10 years since the first biosimilar was approved by the FDA. The grades on how the market for biosimilars has ...
The Global Remicade Biosimilars Market is expected to grow at 9.32% CAGR from 2025 to 2032. The latest Research report published by CMI with the title "An Increase in Demand and Opportunities for ...
FourStatesHomepage.com on MSN3d
‘My health is in jeopardy’: Insurance denies Kansas nursing student’s prescriptionA college student from Anthony is speaking out after Blue Cross and Blue Shield of Kansas denied a medicine she has been ...
Celltrion, Inc., a leading global biopharmaceutical company, announced today that its infliximab biosimilar will be marketed in Canada under the new b ...
Although more research is needed in pediatric patients, biosimilars could improve treatment access and reduce costs.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback